Abstracts tagged "patient outcomes"

Abstract Number: 834 • 2019 ACR/ARP Annual Meeting
Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges
Shanthini Kasturi¹, John Wong ¹, Lisa Mandl ², Timothy McAlindon ³ and Amy LeClair ¹, ¹Tufts Medical Center, Boston, ²Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ³Tufts Medical Center, Boston, MA
Background/Purpose: There is growing interest in the implementation of patient-reported outcome measures (PROMs) in clinical rheumatology to promote patient-centered care and to meet the mandates…
Abstract Number: 876 • 2019 ACR/ARP Annual Meeting
“When You Read This, You Really Feel Old!” Perspectives of Young People with Inflammatory Arthritis on Patient Reported Outcome Measures from a European Qualitative Study
Erika Mosor¹, Paul Studenic ¹, Alessia Alunno ², Ivan Padjen ³, Wendy Olsder ⁴, Sofia Ramiro ⁵, Ilaria Bini ⁶, Nele Caeyers ⁷, Laure Gossec ⁸, Marios Kouloumas ⁹, Elena Nikiphorou ¹⁰, Simon Stones ¹¹, Tanita Wilhelmer ¹² and Tanja Stamm ¹, ¹Medical University of Vienna, Vienna, Austria, ²Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ³UHC Zagreb and University of Zagreb School of Medicine, Zagreb, Croatia, ⁴Patient Research Partner, Amsterdam, Netherlands, ⁵Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ⁶ANMAR Young Patient Advocate, Avellino, Italy, ⁷Patient Research Partner, Brussels, Belgium, ⁸Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁹Cyprus League Against Rheumatism, Nicosia, Cyprus, ¹⁰King's College London, London, United Kingdom, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Österreichische Rheumaliga, Bregenz, Austria
Background/Purpose: Although patient-reported outcome measures (PROMs) are extensively used in clinical practice and research, it is unclear whether the most commonly used instruments adequately cover…
Abstract Number: 1153 • 2019 ACR/ARP Annual Meeting
Double Trouble: Utility of Serial TB Screening in a Rheumatology Clinic Serving a Foreign-Born Population
Alice Fike¹, Yanira Ruiz-Perdomo ¹ and James Katz ¹, ¹NIAMS, BETHESDA, MD
Background/Purpose: The potential for reactivation of tuberculosis (TB) in patients treated with anti-TNF or other immunosuppressive agents has been well described. Interferon-gamma release assays (IGRA)…
Abstract Number: 1327 • 2019 ACR/ARP Annual Meeting
The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
Yusuf Yazici¹, Sarah Kennedy ², Chris Swearingen ² and Jeyanesh Tambiah ², ¹Samumed, LLC, San Diego, CA, ²Samumed, LLC, San Diego
Background/Purpose: Lorecivivint (LOR, SM04690) is a small-molecule, intra-articular (IA) CLK/DYRK1A inhibitor which modulates the Wnt pathway and has demonstrated beneficial effects on patient-reported outcomes (PROs)…
Abstract Number: 1361 • 2019 ACR/ARP Annual Meeting
Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes
Jatin Mistry ¹, Margaret Sibley ², Catherine Smith ³, Malama Sumbwanyambe ² and Patrick Kiely², ¹St George's University of London, London, United Kingdom, ²St George's University Hospitals NHS Trust, London, United Kingdom, ³St Georges University Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: ACR/EULAR guidelines recommend remission or low DAS28 as the treat to target goal for patients with rheumatoid arthritis (RA). Alternative patient reported outcomes include…
Abstract Number: 1839 • 2019 ACR/ARP Annual Meeting
Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis
Hubert de BOYSSON¹, Eric LIOZON ², Olivier ESPITIA ³, Aurélie DAUMAS ⁴, Mathieu VAUTIER ⁵, Marc LAMBERT ⁶, Jean-Jacques PARIENTI ⁷, Alain MANRIQUE ⁷, David Saadoun ⁸, Kim Heang Ly ², Christian Agard ⁹ and Achille Aouba ¹⁰, ¹University Hospital of Caen, Caen, France, ²Limoges University Hospital, Limoges, France, ³Nantes University Hospital, Nantes, France, ⁴Marseille AP-HM, Marseille, France, ⁵Paris - Pitié salpétrière, Paris, France, ⁶Lille University Hospital, Lille, France, ⁷Caen University Hospital, Caen, France, ⁸AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ⁹CHU Nantes, Nantes, France, ¹⁰CHU Caen, Caen, France
Background/Purpose: Large-vessel involvements (LVI) in giant-cell arteritis (GCA) include different clinical and imaging patterns that are often pooled together in the published cohorts under the…
Abstract Number: 2192 • 2019 ACR/ARP Annual Meeting
Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA
Dawn McGuire¹, Michael Bowes ², Alan Brett ², Neil Segal ³, Meghan Miller ⁴, David Rosen ⁴ and Yoshinari Kumagai ⁴, ¹OrthoTrophix, Orinda, CA, ²Imorphics, Manchester, England, United Kingdom, ³University of Kansas Medical Center, Kansas City, KS, ⁴OrthoTrophix, Oakland, CA
Background/Purpose: Based on data from the Osteoarthritis Initiative (OAI), MRI-based analyses of bone shape changes in the knee predict symptomatic and radiographic progression of knee…
Abstract Number: 2242 • 2019 ACR/ARP Annual Meeting
Evaluating Important Change in Cutaneous Disease Activity as an Efficacy Measure for Clinical Trials in Dermatomyositis
Sarah Ahmed¹, Srita Chakka ², Rebecca Krain ³, Rui Feng ⁴ and Victoria Werth ⁵, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia, ⁵Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA
Background/Purpose: The FDA uses near or total clearance in cutaneous disease in inflammatory skin conditions as an endpoint in clinical trials. However, patients may experience…
Abstract Number: 326 • 2018 ACR/ARHP Annual Meeting
Implementation of a Treat-to-Target Quality Improvement Program for Rheumatoid Arthritis Management Using Real-Time Patient Reported Outcome Measures
Malka Forman¹, Cianna Leatherwood², Chang Xu¹, Eunji Ko¹, Bing Lu³, Maura D. Iversen⁴, Daniel Solomon² and Sonali Desai², ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Changing clinical practice patterns and incorporation patient-reported outcome measures (PROMs) for disease activity assessment into routine workflow is challenging. We sought to integrate a…
Abstract Number: 2590 • 2018 ACR/ARHP Annual Meeting
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Mei Liu², Meghan Glynn², Kelechi Emeanuru², Leslie R Harrold³, Sven Richter⁴, Benoit Guerette⁴ and Philip J. Mease⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Celgene Corporation, Summit, NJ, ⁵Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: The effectiveness of therapies has rarely been studied in the subpopulation of patients with oligoarticular psoriatic arthritis (PsA). The objective of this study was…
Abstract Number: 408 • 2018 ACR/ARHP Annual Meeting
State or Trait: Pain Catastrophizing and Widespread Pain Following TKR and Their Associations with Pain Relief
Emma Lape¹, Faith Selzer^1,2, Jamie E. Collins^3,4, Elena Losina^1,4 and Jeffrey N. Katz^1,4, ¹Orthopedic Surgery, Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ²Department of Orthopedic Surgery, Harvard Medical School, Boston, MA, ³Department of Orthopedic Surgery, Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Boston, MA
Background/Purpose: Pain catastrophizing and widespread pain (WP) —constructs reflecting cognitive processes during the pain experience—predict disability, pain chronicity/severity, and lower quality of life in a…
Abstract Number: 2910 • 2018 ACR/ARHP Annual Meeting
Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials
Liana Fraenkel¹, W. Benjamin Nowell², Carole Wiedmeyer², Zhenglin Wei³, Kaleb Michaud⁴, Tuhina Neogi⁵, Christine Ramsey¹ and David Broniatowski³, ¹Yale University School of Medicine, New Haven, CT, ²Global Healthy Living Foundation, Upper Nyack, NY, ³George Washington University, Washington, DC, ⁴Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Randomized controlled trials currently report benefits and adverse events (AEs) separately, and therefore do not permit comparisons of patients’ overall experiences on one treatment…
Abstract Number: 594 • 2018 ACR/ARHP Annual Meeting
Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE
Anne C. Bay-Jensen¹, Christian S. Thudium¹, Claus Christiansen² and Morten A. Karsdal¹, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark
Background/Purpose: Tocilizumab, anti-interleukin 6 receptor (IL-6R) therapy, is an effective treatment of rheumatoid arthritis (RA). However, a significant amount of patients do not respond adequately…
Abstract Number: 1387 • 2018 ACR/ARHP Annual Meeting
Fatigue in Patients with Rheumatoid Arthritis As Compared to Different Groups of Cancer Patients
Jens Gert Kuipers¹, Michael Koller², Ulrich Rueffer³, Florian Zeman², Karolina Mueller⁴ and Joachim Weis⁵, ¹Clinic for Internal Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, ²Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ³German Fatigue Society, Cologne, Germany, ⁴Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ⁵University Clinic Centre Freiburg, Freiburg, Germany
Background/Purpose: Fatigue is a common symptom in patients with rheumatoid arthritis (RA) as well as patients with cancer. Fatigue considerably reduces the quality of life…
Abstract Number: 1391 • 2018 ACR/ARHP Annual Meeting
Patient-Acceptable Symptom State in Psoriatic Arthritis: Prevalence and Associated Factors in Real Clinical Practice
Rubén Queiro¹, Juan Cañete², Carlos Alberto Montilla-Morales³ and Miguel A. Abad⁴, ¹Rheumatology Division, HUCA, Oviedo, Spain, ²Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ⁴FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are remission or low disease activity. We know little about whether these objectives correlate well with a patient-acceptable…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].